Curated News
By: NewsRamp Editorial Staff
June 18, 2026
MindBio Launches Intox AI for Voice-Based Drug and Fatigue Detection
TLDR
- MindBio's Intox AI offers a non-invasive, cost-effective edge over traditional drug testing, targeting high-value safety markets.
- Intox AI analyzes speech patterns via AI to detect cocaine, cannabis, alcohol, psychedelics, and fatigue in real time.
- MindBio's technology promotes workplace safety by detecting impairment non-invasively, potentially reducing accidents and saving lives.
- MindBio launched Intox AI that detects intoxication and fatigue by analyzing voice patterns, a futuristic approach to safety.
Impact - Why it Matters
This news matters because it introduces a non-invasive, AI-driven solution for detecting impairment in safety-critical industries, potentially reducing workplace accidents and saving lives. Traditional drug and alcohol testing methods are often invasive, costly, and time-consuming; Intox AI offers a quick, affordable alternative that can be deployed in remote locations via Edge AI kiosks. For industries like mining, aviation, and construction, where impairment is a leading cause of incidents, this technology could significantly enhance safety protocols and regulatory compliance.
Summary
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) has announced the launch of Intox AI(TM), a flagship enterprise software platform that leverages voice analysis and artificial intelligence to detect drug use, alcohol intoxication, and human fatigue. The platform is designed to identify indicators associated with a range of substances including cocaine, cannabis, alcohol, narcotics, and psychedelics, as well as assess fatigue levels. This non-invasive, affordable alternative to traditional drug and alcohol testing methods is being prepared for deployment through Edge AI kiosk systems, with the first prototypes expected to be completed during the current quarter. The company is targeting safety-critical industries such as mining, aviation, construction, transportation, and law enforcement for commercialization.
MindBio’s transition from research and clinical development to commercial implementation represents a significant milestone. The Intox AI(TM) platform aims to enhance workplace safety by providing real-time, accurate detection of impairment without the need for invasive procedures or costly equipment. By analyzing speech patterns, the technology can quickly assess whether an individual is under the influence of substances or suffering from fatigue, which are major contributors to accidents in high-risk environments. The company’s focus on Edge AI kiosk systems ensures that the software can be deployed locally, reducing latency and dependence on cloud connectivity, making it suitable for remote or offline work sites.
InvestorWire, a specialized communications platform, is syndicating this news as part of its service to highlight emerging opportunities in the biotech and safety-tech sectors. For more details on MindBio’s technology and market strategy, interested parties can access the full release via the provided link. The company’s newsroom also offers ongoing updates for investors following MBQIF.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, MindBio Launches Intox AI for Voice-Based Drug and Fatigue Detection
